Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of... More
Inovio Inks Stock Sales Agreement With Cowan And Company 0 comments
Jun 4, 2012 9:40 AM
Inovio Pharmaceuticals (MKT:INO) said late Friday that it entered into a sales agreement with broker dealer Cowan and Company LLC to sell common stock.
The U.S.-based company may offer and sell its stock for total proceeds worth $25 million. Inovio could sell their stock through Cowan by an "at the market" (ATM) offering on the New York Stock Exchange MKT, or through a market maker.
In addition, Inovio's shares could also be sold through negotiated transactions. This ATM replaces the prior ATM contract the company already had in place.
The company develops DNA-based vaccines to treat and prevent cancers and infectious diseases.
The company's SynCon vaccines are designed to provide broad cross-strain protection against known and newly emergent unmatched strains of pathogens such as influenza.
These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown to generate positive immune responses, along with a favourable safety profile.
Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and the hepatitis C virus and phase I studies for influenza and HIV.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
Inovio Inks Stock Sales Agreement With Cowan And Company 0 comments
Inovio Pharmaceuticals (MKT:INO) said late Friday that it entered into a sales agreement with broker dealer Cowan and
Company LLC to sell common stock.
The U.S.-based company may offer and sell its stock for total proceeds worth $25 million. Inovio could sell their stock through Cowan by an "at the market" (ATM) offering on the New York Stock Exchange MKT, or through a market maker.
In addition, Inovio's shares could also be sold through negotiated transactions. This ATM replaces the prior ATM contract the company already had in place.
The company develops DNA-based vaccines to treat and prevent cancers and infectious diseases.
The company's SynCon vaccines are designed to provide broad cross-strain protection against known and newly emergent unmatched strains of pathogens such as influenza.
These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown to generate positive immune responses, along with a favourable safety profile.
Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and the hepatitis C virus and phase I studies for influenza and HIV.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Share this Instablog
Latest Followers
Latest Comments
Most Commented
Posts by Themes